BRCA-P: An international randomised phase III study evaluating the RANK ligand inhibitor denosumab for the prevention of breast cancer in BRCA1 mutation carriers
Description: Women with a faulty BRCA1 gene are at high lifetime risk for breast cancer. Identifying a safe and effective prevention therapy is therefore a ‘holy grail’. We have discovered that denosumab, used to treat osteoporosis or breast cancer spread to bone, could be ‘repurposed’ as a prevention drug. BRCA-P is an international randomised controlled study that will determine if denosumab prevents breast cancer. Associated translational research will facilitate swift transfer to the clinic.
Amount: A$2,589,000
Funding type: research
Funder scheme: Project Grants - Standard Project Grant
Start date: 2018-01-01
End date: 2022-12-31
Investigator: Geoffrey Lindeman
Institution: Walter and Eliza Hall Institute
Topic: Bone Metabolism and Diseases
Subfield: Molecular Biology
Domain: Life Sciences
Funded outputs count: 0
Funder award ID: 1140715
OpenAlex ID: G6751069260